- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02786186
Et register over pasienter med moderat til alvorlig plakkpsoriasis (PURE)
Et register over pasienter med moderat til alvorlig kronisk plakkpsoriasis i Canada og Latin-Amerika (LACan)
The main purpose of the current study will be to provide real - world evidence regarding the safety and effectiveness of secukinumab in the management of patients with moderate to severe chronic plaque psoriasis.
Studieoversikt
Detaljert beskrivelse
PURE is a multi-national, prospective, observational cohort study of patients with moderate to severe chronic plaque psoriasis aimed at assessing the real-world safety and effectiveness of secukinumab and other indicated therapies. The study will enroll patients for whom, prior to and independent of study enrollment, the treating physician has decided to treat with secukinumab, or one of the other indicated therapies regimens approved for the management of moderate to severe chronic plaque psoriasis.
Two study cohorts will be defined by patients treated with secukinumab (Cohort 1), and patients treated with other indicated therapies (systemic, phototherapy, or biologic therapy; Cohort 2). Each investigator will recruit approximately the same number of patients in each treatment arm. 2,500 patients (1,250 patients in each cohort) will be followed over a period of 5 years from the Baseline assessment (Visit 1).
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Caba, Argentina, C1425BEA
- Novartis Investigative Site
-
-
Buenos Aires
-
Adrogué, Buenos Aires, Argentina, B1846DTL
- Novartis Investigative Site
-
CABA, Buenos Aires, Argentina, C1181ACH
- Novartis Investigative Site
-
Caba, Buenos Aires, Argentina, C1024AAO
- Novartis Investigative Site
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1C3
- Novartis Investigative Site
-
-
British Columbia
-
Nanaimo, British Columbia, Canada, V9T 1W1
- Novartis Investigative Site
-
Surrey, British Columbia, Canada, V3R 6A7
- Novartis Investigative Site
-
Surrey, British Columbia, Canada, V3V 0C6
- Novartis Investigative Site
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Novartis Investigative Site
-
Victoria, British Columbia, Canada, V8V 3M9
- Novartis Investigative Site
-
-
Manitoba
-
Brandon, Manitoba, Canada, R7A 0L5
- Novartis Investigative Site
-
Winnepeg, Manitoba, Canada, R3M 1Z9
- Novartis Investigative Site
-
Winnipeg, Manitoba, Canada, R3C 0N2
- Novartis Investigative Site
-
-
New Brunswick
-
Fredericton, New Brunswick, Canada, E3B 1G9
- Novartis Investigative Site
-
Rothesay, New Brunswick, Canada, E2E 5N4
- Novartis Investigative Site
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1A 4Y3
- Novartis Investigative Site
-
St. John's, Newfoundland and Labrador, Canada, A1C 2H5
- Novartis Investigative Site
-
St. John's, Newfoundland and Labrador, Canada, A1E 1V4
- Novartis Investigative Site
-
-
Nova Scotia
-
Kentville, Nova Scotia, Canada, B4N 4K9
- Novartis Investigative Site
-
-
Ontario
-
Cobourg, Ontario, Canada, K9A 4J9
- Novartis Investigative Site
-
Hamilton, Ontario, Canada, L8N 3Z5
- Novartis Investigative Site
-
Hamilton, Ontario, Canada, L9B 1K5
- Novartis Investigative Site
-
London, Ontario, Canada, N6H 5L5
- Novartis Investigative Site
-
London, Ontario, Canada, N6A 2C2
- Novartis Investigative Site
-
London, Ontario, Canada, N6A 3H7
- Novartis Investigative Site
-
Markham, Ontario, Canada, L3P 1X3
- Novartis Investigative Site
-
Mississauga, Ontario, Canada, L4W 0C2
- Novartis Investigative Site
-
Mississauga, Ontario, Canada, L4Y 4C5
- Novartis Investigative Site
-
Nepean, Ontario, Canada, K2G 6E2
- Novartis Investigative Site
-
Niagara Falls, Ontario, Canada, L2H 1H5
- Novartis Investigative Site
-
North York, Ontario, Canada, M3B 3N1
- Novartis Investigative Site
-
Peterborough, Ontario, Canada, K9J 5K2
- Novartis Investigative Site
-
Richmond Hill, Ontario, Canada, L4C 9M7
- Novartis Investigative Site
-
Toronto, Ontario, Canada, M2M 4J5
- Novartis Investigative Site
-
Toronto, Ontario, Canada, M3H 5Y8
- Novartis Investigative Site
-
Toronto, Ontario, Canada, M4W 2N2
- Novartis Investigative Site
-
Waterloo, Ontario, Canada, N2J 1C4
- Novartis Investigative Site
-
Waterloo, Ontario, Canada, N1H 1B1
- Novartis Investigative Site
-
-
Quebec
-
Laval, Quebec, Canada, H7N 6L2
- Novartis Investigative Site
-
Montreal, Quebec, Canada, H3H 1V4
- Novartis Investigative Site
-
Montreal, Quebec, Canada, H2X 1R9
- Novartis Investigative Site
-
-
-
-
-
Santiago de los Caballeros, Den dominikanske republikk, 51000
- Novartis Investigative Site
-
Santo Domingo, Den dominikanske republikk, 10103
- Novartis Investigative Site
-
-
-
-
-
Guatemala City, Guatemala, 01011
- Novartis Investigative Site
-
-
-
-
Estado de Baja California
-
Mexicali, Estado de Baja California, Mexico, 21100
- Novartis Investigative Site
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44638
- Novartis Investigative Site
-
-
Mexico
-
Guadalajara Jalisco, Mexico, Mexico, 44610
- Novartis Investigative Site
-
-
Mexico City
-
Del Tlalpan, Mexico City, Mexico, 14389
- Novartis Investigative Site
-
-
Nuevo León
-
San Pedro G G, Nuevo León, Mexico, 66220
- Novartis Investigative Site
-
-
State of Mexico
-
Toluca, State of Mexico, Mexico, 50120
- Novartis Investigative Site
-
-
-
-
-
Panama City, Panama, 0831
- Novartis Investigative Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Patient with moderate to severe plaque psoriasis
Beskrivelse
Inclusion Criteria:
- - Patients able to give written informed consent
- - Patients at least 18 years of age at time of informed consent signature
- - Confirmed diagnosis of chronic moderate to severe chronic plaque-type psoriasis diagnosed by a specialist and presence of moderate to severe psoriasis symptoms according to physician's clinical judgment at the time of recruitment.
- - Patients initiating a treatment for psoriasis as per regional policy. This will include secukinumab, other biologics, systemic treatments, and phototherapy. Decision to treat with any of the above-mentioned treatments must have been reached prior to and independently of recruitment in the study.
- - Treatments prescribed in accordance to the product monograph and regional regulatory and reimbursement policies
- - Patients able to understand and communicate with the investigator and comply with the requirements of the study.
Exclusion Criteria:
- - Unwillingness or inability to comply with the study requirements
- - Participation in a clinical trial of an investigational drug, concurrently or within the last 30 days.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Secikinumab
Patients treated with secukinumab |
Andre navn:
|
|
Approved standard of care
Patients treated with other indicated therapies (systemic, phototherapy, or biologic therapy) |
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Tidsramme: Change from Baseline through month 60
|
Incidence of all adverse events in the study cohorts as measured by:
|
Change from Baseline through month 60
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Gjennomsnittlig endring for WPAI-poengsum (Work Productivity and Activity Impairment).
Tidsramme: Endring fra baseline til måned 60
|
Endring fra baseline til måned 60
|
|
|
Gjennomsnittlig endring for Hospital Anxiety and Depression Scale (HADS) score
Tidsramme: Endring fra baseline til måned 60
|
Endring fra baseline til måned 60
|
|
|
Gjennomsnittlig endring for Psoriasis Symptom Diary (PSD) poengsum
Tidsramme: Endring fra baseline til måned 60
|
Endring fra baseline til måned 60
|
|
|
Gjennomsnittlig endring for Treatment Satisfaction Scale (TSS) poengsum
Tidsramme: Endring fra baseline til måned 60
|
Endring fra baseline til måned 60
|
|
|
Gjennomsnittlig endring for Dermatology Life Quality Index (DLQI) poengsum
Tidsramme: Endring fra baseline til måned 60
|
Endring fra baseline til måned 60
|
|
|
Gjennomsnittlig endring for Psoriasis Epidemiology Screening Tool (PEST) poengsum
Tidsramme: Endring fra baseline til måned 60
|
Endring fra baseline til måned 60
|
|
|
Gjennomsnittlig endring for direkte og indirekte kostnader knyttet til Psoriasis
Tidsramme: Endring fra baseline til måned 60
|
Endring fra baseline til måned 60
|
|
|
Percentage of Participants Achieving PASI 50/75/90/100 Response or IGA 0 or 1 Response
Tidsramme: Change from Baseline through month 60
|
PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section(head: 0.1, arms: 0.2 body: 0.3 legs: 0.4) |
Change from Baseline through month 60
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Papp KA, Gooderham M, Beecker J, Lynde CW, Delorme I, Dei-Cas I, Albrecht L, Rampakakis E, Sampalis JS, Vieira A, Hussein S, Chambenoit O, Rihakova L. Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America. BMC Dermatol. 2019 Jun 21;19(1):9. doi: 10.1186/s12895-019-0087-3.
- Papp KA, Gooderham M, Dei-Cas I, LopezTello A, Garcia-Rodriguez JC, Taveras CY, Rousselin AH, Lavieri A, Maiolino M, Quintero DGV, Rihakova L, Salibe M, Pertuz W. Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data. Dermatol Ther (Heidelb). 2023 Jan;13(1):269-283. doi: 10.1007/s13555-022-00849-0. Epub 2022 Dec 10.
- Beecker J, Albrecht L, Dei-Cas I, Gooderham M, Lynde C, Papp KA, Keown P, Vieira A, Farag MS, Maguin M, Zappitelli T, Helliwell PS. Longitudinal Performance of the Psoriasis Epidemiology Screening Tool (PEST) in Canada and Latin America: Results from the Prospective, Observational, 5-Year PURE Registry. Dermatol Ther (Heidelb). 2026 Aug;16(8):4097-4115. doi: 10.1007/s13555-026-01826-7. Epub 2026 Jul 21.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Antatt)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CAIN457ACA02
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .